Following on from information provided to NICE by the company in May 2012, the appraisal of Laquinimod for treating relapsing-remitting multiple sclerosis [560] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 560 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Lyndsey Unwin |
| Project manager: | |
| Technical Lead: | Helen Tucker |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2022 | Following on from information provided to NICE by the company in May 2012, the appraisal of Laquinimod for treating relapsing-remitting multiple sclerosis [560] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 31 October 2022 | Discontinued. Following on from information provided to NICE by the company in May 2012, the appraisal of Laquinimod for treating relapsing-remitting multiple sclerosis [560] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 22 July 2014 | We are suspending this appraisal. This is because the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has decided not to approve laquinimod for the treatment of relapsing-remitting multiple sclerosis. |
| 20 May 2014 | Following the opinion recently issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) we are rescheduling this appraisal. NICE cannot issue consultation documents or guidance on a technology until UK regulatory approval has been granted. We will therefore need to reschedule the appraisal to align with the latest regulatory expectations. |
| 03 January 2014 | A further draft scope consultation took place in October 2013 |
For further information on our processes and methods, please see our CHTE processes and methods manual